Which has grown faster, PAHC or RARE?

Over the past five years, RARE grew revenue faster — PAHC at a 12.75% CAGR versus RARE at 14.81%.

Does PAHC or RARE pay a bigger dividend?

PAHC pays a dividend (1.29% yield), while RARE has no payments in the available dividend history.

Is PAHC or RARE more profitable?

PAHC runs the higher net margin — PAHC at 6.57% versus RARE at -81.79%.

How have PAHC and RARE total returns compared?

Over the past 10 years, PAHC delivered 5.27% and RARE delivered -14.91% annualized total return. Past performance doesn't predict future results.

Phibro Animal Health Corporation (PAHC) vs Ultragenyx Pharmaceutical Inc. (RARE)

A side-by-side comparison of Phibro Animal Health Corporation and Ultragenyx Pharmaceutical Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

PAHC

Phibro Animal Health Corporation

$1.48B

$36.61HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

RARE

Ultragenyx Pharmaceutical Inc.

$1.42B

$14.46HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — PAHC vs RARE

growth of $100 · dividends reinvested · last 10y

PAHC +67.9% (+5.3%/yr)RARE -79.2% (-14.5%/yr)PAHC compounded faster over this window

Log scale — wide-divergence pair

PAHC RARE

PAHC vs RARE: by the numbers

•PAHC is the larger company ($1.48B vs $1.42B market cap).
•PAHC is profitable (6.57% net margin) while RARE runs a net loss (-81.79%).
•RARE grew revenue faster over the past five years (14.81% vs 12.75% CAGR).
•PAHC pays a dividend (1.29% yield), while RARE has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	PAHC	RARE
P/E ratio	15.00	N/A
Forward P/E	10.46	N/A
PEG ratio	1.18	N/A
P/S ratio	0.98	1.99
P/B ratio	3.85	N/A
EV / EBITDA	8.85	N/A
FCF yield	0.66%	N/A

Profitability

Metric	PAHC	RARE
Gross margin	33.71%	83.12%
Operating margin	13.07%	-73.77%
Net margin	6.57%	-81.79%
ROE	25.87%	N/A
ROIC	11.91%	-53.48%

Dividends

Metric	PAHC	RARE
Dividend yield	1.29%	N/A
Payout ratio	19.67%	N/A

Growth (annualized)

Metric	PAHC	RARE
Revenue CAGR (5Y)	12.75%	14.81%
EPS CAGR (5Y)	12.92%	N/A
FCF CAGR (5Y)	-12.27%	N/A
Total return CAGR (5Y)	14.40%	-30.14%

Frequently asked

Which has grown faster, PAHC or RARE?: Over the past five years, RARE grew revenue faster — PAHC at a 12.75% CAGR versus RARE at 14.81%.
Does PAHC or RARE pay a bigger dividend?: PAHC pays a dividend (1.29% yield), while RARE has no payments in the available dividend history.
Is PAHC or RARE more profitable?: PAHC runs the higher net margin — PAHC at 6.57% versus RARE at -81.79%.
How have PAHC and RARE total returns compared?: Over the past 10 years, PAHC delivered 5.27% and RARE delivered -14.91% annualized total return. Past performance doesn't predict future results.

Go deeper

Full PAHC analysis Full RARE analysis Interactive comparison tool

Dig into the metrics

Phibro Animal Health P/E ratio Phibro Animal Health dividend yield Phibro Animal Health ROE Ultragenyx Pharmaceutical ROE Phibro Animal Health operating margin Ultragenyx Pharmaceutical operating margin Phibro Animal Health revenue growth Ultragenyx Pharmaceutical revenue growth Phibro Animal Health free cash flow Ultragenyx Pharmaceutical free cash flow

Phibro Animal Health & Ultragenyx Pharmaceutical appear in these rankings

Highest ROE Stocks Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.